美国新生血管性年龄相关性黄斑变性的管理与结局:电子健康记录分析
结果显示,首年平均就诊8.1次、注射6.0次、OCT检查7.2次,平均中心视网膜厚度(CRT)下降48μm,视力平均仅提高0.6个近似ETDRS字母。注射频率较低,解剖改善中等而视力获益有限。
要点
- 首年平均抗VEGF注射仅6.0次,就诊8.1次,OCT检查7.2次。
- 平均CRT从320μm降至271μm,视力平均提高0.6个字母。
- 注射≥7次者视力平均提高1.79个字母,<7次者平均下降0.95个字母。
核心结论
- 美国临床实践中nAMD患者抗VEGF注射频率相对较低,解剖改善中等而视力获益有限。
主要发现
- 首12个月平均每只研究眼接受6.0次注射(范围1-27)、7.2次OCT和5.3次荧光素血管造影(FA)检查,平均就诊8.1次(范围1-39)。
- 有基线和12个月配对数据的眼,平均CRT从320μm降至271μm(平均变化-48μm),平均视力从60.3个近似ETDRS字母提高到61.0个字母(平均变化+0.6个字母)。
- 贝伐珠单抗、雷珠单抗和阿柏西普起始治疗后12个月,分别有19.3%、15.8%和15.5%的眼视力提高>10个字母,分别有13.2%、14.7%和14.4%的眼视力下降>10个字母。
- 12个月视力平均变化随累积注射次数线性增加:注射≥7次者+1.79个近似ETDRS字母,注射<7次者-0.95个字母。
- 多变量线性回归校正协变量后,累积抗VEGF注射次数与12个月视力变化显著相关,每增加一次注射估计增加0.37个近似ETDRS字母。
临床怎么用
- 应关注真实世界中抗VEGF注射频率不足的问题,适当增加注射和监测频次可能改善视力结局。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess anti-vascular endothelial growth factor (VEGF) management patterns and anatomic and visual acuity (VA) outcomes among patients with neovascular age-related macular degeneration (nAMD) in United States clinical practice. DESIGN: Retrospective observational cohort study. PARTICIPANTS: Patients (N = 30 106) initiating intravitreal anti-VEGF treatment for nAMD between October 2009 and November 2016. METHODS: Analysis of longitudinal electronic health records from USRetina. MAIN OUTCOME MEASURES: Number of intravitreal injections, OCT examinations, and fluorescein angiography (FA) examinations per study eye during the first 12 months; corrected VA and central retinal thickness (CRT) at 12 months; and number of ophthalmologist visits, stratified by index anti-VEGF agent. RESULTS: Over the first 12 months, patients made a mean of 8.1 (range, 1-39) ophthalmologist visits, received a mean of 6.0 (range, 1-27) anti-VEGF injections, and underwent 7.2 OCT and 5.3 FA examinations per study eye. For eyes with paired baseline and 12-month readings, mean CRT declined from 320 to 271 μm (mean change, -48 μm), and mean VA increased from 60.3 to 61.0 approximate Early Treatment Diabetic Retinopathy Study (ETDRS) letters (mean change, +0.6 letters). Twelve months after initiating index treatment with bevacizumab, ranibizumab, and aflibercept, 19.3%, 15.8%, and 15.5% of eyes, respectively, showed greater than 10-letter gain, whereas 13.2%, 14.7%, and 14.4% of eyes, respectively, showed greater than 10-letter loss. Mean change from baseline VA at 12 months increased linearly with cumulative anti-VEGF injection count: +1.79 versus -0.95 approximate ETDRS letters for eyes receiving 7 or more injections versus fewer than 7 injections. Similarly, the magnitude of the reduction from baseline CRT at 12 months tended to increase linearly with increasing number of anti-VEGF injections. Multivariate linear regression analysis, adjusted for covariates, indicated a significant association between cumulative number of anti-VEGF injections and change from baseline in VA at 12 months, with each unit increase producing an estimated gain of 0.37 approximate ETDRS letters. CONCLUSIONS: This analysis of combined morphologic and functional outcomes of anti-VEGF therapy, the largest conducted to date in nAMD, identified relatively low anti-VEGF injection frequencies, coupled with moderate anatomic and limited VA improvements, in United States clinical practice.
引用
- Kiss S, Campbell J, Almony A, et al. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records. Ophthalmology. 2020. PMID: 32345477. doi:10.1016/j.ophtha.2020.02.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。